| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 96361 |
Intravenous infusion, hydration; each additional hour |
19,049 |
14,855 |
$7.39M |
| 36415 |
Collection of venous blood by venipuncture |
60,306 |
42,706 |
$5.68M |
| 80053 |
Comprehensive metabolic panel |
66,140 |
53,394 |
$3.96M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
28,088 |
17,982 |
$3.30M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
47,226 |
11,922 |
$2.37M |
| 76376 |
|
20,959 |
18,730 |
$2.04M |
| 80048 |
Basic metabolic panel (calcium, ionized) |
32,159 |
25,191 |
$2.00M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
8,163 |
6,535 |
$1.92M |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
13,478 |
12,284 |
$1.85M |
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
31,777 |
29,587 |
$1.36M |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
17,988 |
4,887 |
$1.24M |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
1,483 |
1,436 |
$1.12M |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
5,240 |
5,018 |
$1.01M |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
2,068 |
1,972 |
$1.01M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
8,707 |
8,174 |
$927K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
4,892 |
4,368 |
$696K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
27,991 |
24,122 |
$691K |
| 82565 |
|
1,773 |
1,697 |
$669K |
| 81025 |
|
16,930 |
15,337 |
$593K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
371 |
341 |
$544K |
| 72141 |
|
921 |
888 |
$541K |
| 93922 |
|
2,148 |
2,095 |
$509K |
| 0241U |
Neonatal screening for hereditary disorders, genomic sequence analysis panel |
6,218 |
5,975 |
$440K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
15,670 |
5,577 |
$439K |
| 93971 |
|
1,810 |
1,727 |
$439K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
753 |
729 |
$431K |
| 71046 |
Radiologic examination, chest; 2 views |
17,628 |
16,474 |
$426K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
9,561 |
9,125 |
$416K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
16,364 |
12,771 |
$389K |
| 81001 |
|
30,745 |
27,393 |
$382K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
20,858 |
18,600 |
$356K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
18,159 |
16,783 |
$341K |
| 86900 |
|
3,456 |
3,166 |
$326K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
17,981 |
15,772 |
$311K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
10,803 |
9,406 |
$303K |
| J7050 |
Infusion, normal saline solution, 250 cc |
15,669 |
7,951 |
$302K |
| 93880 |
|
1,347 |
1,289 |
$293K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
3,504 |
3,297 |
$283K |
| 82962 |
|
18,708 |
7,480 |
$280K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
26,044 |
23,935 |
$277K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
8,316 |
4,266 |
$264K |
| 94060 |
|
728 |
715 |
$248K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
1,367 |
1,331 |
$242K |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
2,059 |
2,050 |
$235K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
3,333 |
3,202 |
$217K |
| 93225 |
|
676 |
664 |
$206K |
| 76816 |
Ultrasound, pregnant uterus, real time with image documentation, follow-up |
906 |
681 |
$197K |
| 73610 |
|
2,538 |
2,314 |
$188K |
| 93017 |
|
2,063 |
1,991 |
$182K |
| 87081 |
|
5,614 |
5,445 |
$181K |
| 94010 |
|
1,991 |
1,460 |
$175K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
3,041 |
1,985 |
$169K |
| 87077 |
|
6,527 |
6,187 |
$164K |
| 73130 |
|
2,189 |
1,853 |
$157K |
| 77062 |
|
866 |
834 |
$153K |
| 73564 |
|
3,358 |
2,962 |
$153K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
9,787 |
8,678 |
$150K |
| 73030 |
|
2,383 |
2,181 |
$149K |
| 95886 |
|
1,065 |
1,055 |
$146K |
| 73630 |
|
3,294 |
2,826 |
$145K |
| 93970 |
|
767 |
725 |
$137K |
| 72040 |
|
2,071 |
1,984 |
$134K |
| 97161 |
|
4,573 |
4,413 |
$133K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
89,682 |
66,706 |
$133K |
| 76830 |
Ultrasound, transvaginal |
1,662 |
1,589 |
$132K |
| 73110 |
|
1,479 |
1,374 |
$132K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
1,065 |
1,000 |
$131K |
| 81003 |
|
7,183 |
6,706 |
$123K |
| 87210 |
|
2,662 |
2,424 |
$123K |
| 74018 |
|
2,870 |
2,698 |
$122K |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
3,629 |
1,844 |
$118K |
| 72100 |
|
3,336 |
3,180 |
$118K |
| 84702 |
|
3,020 |
2,305 |
$118K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
1,941 |
1,909 |
$112K |
| 0001A |
|
1,648 |
1,561 |
$103K |
| 87070 |
|
3,413 |
3,318 |
$101K |
| G0378 |
Hospital observation service, per hour |
18,821 |
8,240 |
$96K |
| 73221 |
|
164 |
160 |
$96K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
4,613 |
4,025 |
$96K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
27,737 |
21,574 |
$92K |
| 0002A |
|
1,526 |
1,495 |
$90K |
| 71045 |
Radiologic examination, chest; single view |
13,739 |
12,044 |
$89K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
11,895 |
11,071 |
$88K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
1,144 |
965 |
$87K |
| 86780 |
|
4,064 |
3,820 |
$86K |
| 82803 |
|
1,976 |
1,574 |
$86K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,387 |
1,283 |
$82K |
| 76536 |
|
1,066 |
1,048 |
$82K |
| 70450 |
Computed tomography, head or brain; without contrast material |
8,013 |
7,464 |
$80K |
| 93270 |
|
338 |
330 |
$80K |
| 76775 |
|
1,189 |
1,132 |
$77K |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
2,804 |
2,643 |
$75K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
2,563 |
2,453 |
$72K |
| 71250 |
|
1,628 |
1,571 |
$72K |
| 92523 |
|
612 |
602 |
$72K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
29,046 |
25,592 |
$71K |
| 76377 |
|
584 |
527 |
$71K |
| 74022 |
|
3,506 |
3,242 |
$69K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
3,418 |
1,048 |
$69K |
| 77061 |
|
430 |
424 |
$67K |
| 73090 |
|
672 |
621 |
$64K |
| J3490 |
Unclassified drugs |
27,867 |
15,736 |
$64K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
1,853 |
1,769 |
$63K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
3,590 |
1,982 |
$63K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
6,315 |
5,917 |
$63K |
| 97162 |
|
2,926 |
2,778 |
$62K |
| 80074 |
|
1,274 |
1,239 |
$60K |
| 76642 |
|
1,788 |
1,568 |
$59K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
3,147 |
3,099 |
$58K |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
20,090 |
10,127 |
$57K |
| 72120 |
|
539 |
526 |
$56K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
455 |
450 |
$56K |
| 96367 |
|
664 |
418 |
$55K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
407 |
393 |
$51K |
| 73140 |
|
342 |
327 |
$51K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
1,381 |
1,338 |
$50K |
| 73502 |
|
1,605 |
1,502 |
$50K |
| 80061 |
Lipid panel |
16,241 |
15,846 |
$48K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
178 |
169 |
$47K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
2,702 |
2,612 |
$47K |
| 36600 |
|
900 |
789 |
$47K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
7,816 |
4,736 |
$45K |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
371 |
268 |
$45K |
| 73080 |
|
475 |
440 |
$44K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
9,447 |
7,721 |
$44K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
2,011 |
1,985 |
$40K |
| 73590 |
|
885 |
784 |
$40K |
| 83655 |
|
3,272 |
3,203 |
$39K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
6,602 |
6,382 |
$39K |
| 77336 |
|
181 |
74 |
$39K |
| T1015 |
Clinic visit/encounter, all-inclusive |
1,962 |
1,910 |
$38K |
| 85027 |
|
9,695 |
8,485 |
$37K |
| 97113 |
|
1,177 |
317 |
$36K |
| 64483 |
|
1,713 |
1,673 |
$33K |
| 87428 |
|
400 |
389 |
$33K |
| U0001 |
Cdc 2019 novel coronavirus (2019-ncov) real-time rt-pcr diagnostic panel |
8,016 |
7,409 |
$31K |
| 84443 |
Thyroid stimulating hormone (TSH) |
22,370 |
21,217 |
$31K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
123 |
121 |
$31K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
10,280 |
9,925 |
$30K |
| 85018 |
|
2,757 |
2,536 |
$29K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
4,006 |
3,102 |
$29K |
| J1644 |
Injection, heparin sodium, per 1000 units |
8,138 |
3,222 |
$28K |
| 85610 |
|
14,405 |
12,191 |
$27K |
| 80081 |
|
227 |
222 |
$26K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
7,062 |
6,670 |
$26K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
7,767 |
5,828 |
$24K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
717 |
707 |
$24K |
| 88300 |
|
1,538 |
1,532 |
$24K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
15,693 |
12,191 |
$24K |
| 88304 |
|
1,381 |
1,344 |
$24K |
| 88142 |
|
2,527 |
2,439 |
$24K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
13,936 |
11,534 |
$23K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
64 |
64 |
$22K |
| 72070 |
|
613 |
581 |
$22K |
| 12001 |
|
184 |
181 |
$22K |
| 84439 |
|
4,758 |
4,544 |
$22K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
7,790 |
6,845 |
$21K |
| 87807 |
|
967 |
933 |
$21K |
| 93246 |
|
214 |
211 |
$20K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
8,117 |
6,540 |
$20K |
| 76801 |
|
662 |
591 |
$20K |
| 94760 |
|
4,447 |
2,551 |
$19K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
783 |
775 |
$19K |
| 81000 |
|
2,209 |
2,051 |
$19K |
| 76641 |
|
630 |
532 |
$19K |
| 84112 |
|
157 |
143 |
$18K |
| 72158 |
|
41 |
39 |
$18K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
1,344 |
1,072 |
$17K |
| 11042 |
Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm |
125 |
85 |
$17K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
3,074 |
2,884 |
$16K |
| 10035 |
|
179 |
154 |
$16K |
| 82570 |
|
4,333 |
4,008 |
$16K |
| 82247 |
|
684 |
368 |
$15K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
2,690 |
1,097 |
$15K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
6,005 |
5,394 |
$15K |
| 97164 |
|
1,834 |
1,645 |
$15K |
| 86592 |
|
1,017 |
920 |
$15K |
| G0008 |
Administration of influenza virus vaccine |
536 |
516 |
$14K |
| 82728 |
|
4,871 |
4,615 |
$14K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
6,466 |
4,804 |
$14K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
824 |
541 |
$14K |
| 83735 |
|
27,468 |
19,162 |
$14K |
| 94664 |
|
5,827 |
4,084 |
$13K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
4,578 |
3,639 |
$13K |
| A4217 |
Sterile water/saline, 500 ml |
90 |
75 |
$13K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
171 |
165 |
$13K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
2,744 |
2,667 |
$13K |
| 93925 |
|
291 |
291 |
$13K |
| 97166 |
|
730 |
661 |
$12K |
| 97165 |
|
844 |
789 |
$12K |
| 86850 |
|
2,955 |
2,701 |
$12K |
| 93458 |
|
14 |
14 |
$12K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
7,364 |
6,563 |
$11K |
| 85730 |
|
13,009 |
11,161 |
$11K |
| J3480 |
Injection, potassium chloride, per 2 meq |
2,013 |
1,184 |
$11K |
| 95806 |
|
102 |
100 |
$11K |
| 97116 |
|
4,308 |
1,568 |
$11K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
6,232 |
2,498 |
$11K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
1,794 |
1,232 |
$11K |
| J2060 |
Injection, lorazepam, 2 mg |
1,955 |
1,531 |
$11K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
3,471 |
2,995 |
$10K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
364 |
344 |
$10K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
4,343 |
3,906 |
$10K |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
82 |
72 |
$10K |
| 82607 |
|
3,147 |
3,025 |
$10K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
255 |
233 |
$10K |
| 99152 |
|
602 |
552 |
$10K |
| 83540 |
|
5,559 |
5,274 |
$9K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
472 |
468 |
$9K |
| 0004A |
|
235 |
178 |
$9K |
| 86140 |
|
3,986 |
3,573 |
$9K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
1,123 |
1,099 |
$9K |
| 84484 |
|
22,351 |
12,868 |
$9K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
186 |
180 |
$8K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
4,641 |
3,579 |
$8K |
| 93990 |
|
38 |
37 |
$8K |
| 11719 |
|
347 |
339 |
$8K |
| 73552 |
|
362 |
324 |
$8K |
| 72110 |
|
88 |
87 |
$8K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
129 |
120 |
$8K |
| 80076 |
|
2,514 |
2,232 |
$8K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
88 |
78 |
$8K |
| 87045 |
|
257 |
249 |
$7K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
363 |
324 |
$7K |
| 86901 |
|
3,771 |
3,453 |
$7K |
| 82043 |
|
1,226 |
1,203 |
$7K |
| 81002 |
|
578 |
517 |
$7K |
| 87205 |
|
2,884 |
2,733 |
$7K |
| 87280 |
|
60 |
56 |
$7K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
2,245 |
2,124 |
$7K |
| 86038 |
|
1,158 |
1,128 |
$7K |
| 87040 |
|
6,802 |
3,860 |
$6K |
| 77065 |
Tomosynthesis, mammo |
536 |
525 |
$6K |
| 77066 |
Tomosynthesis, mammo |
921 |
885 |
$6K |
| 74220 |
|
143 |
135 |
$6K |
| 80055 |
|
29 |
29 |
$6K |
| 96523 |
|
709 |
549 |
$6K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
1,116 |
821 |
$6K |
| 84145 |
|
1,079 |
969 |
$6K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
1,455 |
1,183 |
$6K |
| C9113 |
Injection, pantoprazole sodium, per vial |
2,233 |
1,239 |
$5K |
| 85379 |
|
3,151 |
2,929 |
$5K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
1,944 |
1,866 |
$5K |
| 0072A |
|
110 |
109 |
$5K |
| J1940 |
Injection, furosemide, up to 20 mg |
915 |
548 |
$5K |
| 71101 |
|
97 |
95 |
$4K |
| 84466 |
|
4,962 |
4,717 |
$4K |
| 83605 |
|
6,021 |
4,459 |
$4K |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
697 |
351 |
$4K |
| 84153 |
|
759 |
724 |
$4K |
| 84156 |
|
3,042 |
2,700 |
$4K |
| 82731 |
|
67 |
62 |
$4K |
| 10060 |
|
30 |
28 |
$4K |
| 87046 |
|
269 |
261 |
$4K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
4,001 |
3,852 |
$4K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
134 |
123 |
$4K |
| 76942 |
|
1,057 |
976 |
$4K |
| 80051 |
|
771 |
700 |
$4K |
| J2704 |
Injection, propofol, 10 mg |
5,345 |
4,964 |
$4K |
| 0054A |
|
106 |
99 |
$4K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
9,272 |
8,804 |
$4K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
4,416 |
3,383 |
$4K |
| 90715 |
|
1,576 |
1,524 |
$4K |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
46 |
44 |
$4K |
| J1815 |
Injection, insulin, per 5 units |
1,750 |
994 |
$4K |
| 93242 |
|
57 |
56 |
$4K |
| 71271 |
|
12 |
12 |
$4K |
| J1756 |
Injection, iron sucrose, 1 mg |
396 |
196 |
$4K |
| 0071A |
|
85 |
82 |
$3K |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
83 |
69 |
$3K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
187 |
161 |
$3K |
| 80305 |
|
49 |
47 |
$3K |
| 93926 |
|
39 |
38 |
$3K |
| 84550 |
|
1,974 |
1,854 |
$3K |
| 97535 |
Self-care/home management training, each 15 minutes |
1,085 |
605 |
$3K |
| 73060 |
|
55 |
51 |
$3K |
| 62321 |
|
56 |
55 |
$3K |
| 90686 |
|
735 |
717 |
$3K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
1,568 |
1,167 |
$3K |
| 82140 |
|
477 |
411 |
$3K |
| 82550 |
|
3,174 |
2,747 |
$3K |
| 76882 |
|
38 |
38 |
$2K |
| 78227 |
|
12 |
12 |
$2K |
| 83880 |
|
3,494 |
3,035 |
$2K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
392 |
372 |
$2K |
| 83690 |
|
12,437 |
10,919 |
$2K |
| 70360 |
|
40 |
39 |
$2K |
| 95911 |
|
71 |
70 |
$2K |
| 90791 |
Psychiatric diagnostic evaluation |
17 |
15 |
$2K |
| 86803 |
|
2,741 |
2,684 |
$2K |
| 20611 |
|
68 |
50 |
$2K |
| 82950 |
|
213 |
211 |
$2K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
163 |
124 |
$2K |
| 84100 |
|
3,774 |
2,997 |
$2K |
| 72170 |
|
137 |
130 |
$2K |
| 76857 |
|
671 |
646 |
$1K |
| J2919 |
Injection, methylprednisolone sodium succinate, 5 mg |
266 |
186 |
$1K |
| Q9961 |
High osmolar contrast material, 250-299 mg/ml iodine concentration, per ml |
54 |
50 |
$1K |
| 96376 |
|
3,448 |
2,779 |
$1K |
| 86762 |
|
160 |
158 |
$1K |
| G0379 |
Direct admission of patient for hospital observation care |
662 |
604 |
$1K |
| 70486 |
|
158 |
155 |
$1K |
| 82785 |
|
31 |
31 |
$1K |
| 0052A |
|
42 |
42 |
$1K |
| 93325 |
|
59 |
56 |
$1K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
55 |
55 |
$1K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
487 |
416 |
$1K |
| 87641 |
|
304 |
274 |
$1K |
| 88173 |
|
12 |
12 |
$1K |
| 82077 |
|
3,332 |
2,982 |
$1K |
| J2785 |
Injection, regadenoson, 0.1 mg |
754 |
727 |
$1K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
41 |
38 |
$989.60 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
3,061 |
2,220 |
$941.12 |
| 64493 |
|
125 |
121 |
$918.20 |
| 74178 |
|
14 |
13 |
$856.37 |
| 73560 |
|
62 |
52 |
$829.31 |
| 83001 |
|
14 |
14 |
$799.07 |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
18 |
18 |
$796.92 |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
23 |
17 |
$756.63 |
| 0051A |
|
20 |
18 |
$673.12 |
| 83970 |
|
1,998 |
1,894 |
$662.64 |
| 93976 |
|
44 |
40 |
$636.65 |
| 70491 |
|
92 |
89 |
$635.82 |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
12 |
12 |
$615.45 |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
178 |
156 |
$583.20 |
| 27096 |
|
12 |
12 |
$574.18 |
| 93247 |
|
16 |
15 |
$565.25 |
| 96161 |
|
15 |
14 |
$522.00 |
| 94726 |
|
90 |
90 |
$492.82 |
| 84132 |
|
28 |
25 |
$487.47 |
| 59025 |
Fetal non-stress test |
72 |
59 |
$471.35 |
| 86580 |
|
58 |
55 |
$462.30 |
| J2470 |
Injection, pantoprazole sodium, 40 mg |
169 |
93 |
$457.37 |
| 96127 |
|
14 |
14 |
$392.00 |
| 82784 |
|
91 |
89 |
$362.15 |
| 84480 |
|
2,884 |
2,741 |
$337.64 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
539 |
439 |
$306.11 |
| 85652 |
|
5,173 |
4,767 |
$305.59 |
| 82150 |
|
315 |
301 |
$269.35 |
| 84146 |
|
16 |
12 |
$250.05 |
| 36591 |
|
76 |
51 |
$242.10 |
| 82652 |
|
20 |
16 |
$225.58 |
| 92610 |
|
15 |
14 |
$220.22 |
| 86003 |
|
102 |
102 |
$215.60 |
| G0297 |
Low dose ct scan (ldct) for lung cancer screening |
12 |
12 |
$208.46 |
| 70496 |
|
13 |
13 |
$203.87 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
1,736 |
1,660 |
$198.35 |
| 84403 |
|
74 |
70 |
$169.68 |
| 82553 |
|
2,019 |
1,813 |
$168.78 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
26 |
24 |
$144.15 |
| 84681 |
|
124 |
115 |
$138.14 |
| 87186 |
|
5,962 |
5,655 |
$122.47 |
| 84703 |
|
13 |
13 |
$113.46 |
| 86141 |
|
414 |
395 |
$111.06 |
| 88160 |
|
13 |
12 |
$92.08 |
| 88342 |
|
149 |
135 |
$86.21 |
| 88307 |
|
49 |
45 |
$78.77 |
| 82105 |
|
12 |
12 |
$63.31 |
| A9502 |
Technetium tc-99m tetrofosmin, diagnostic, per study dose |
1,194 |
1,128 |
$38.13 |
| 90656 |
|
15 |
15 |
$37.15 |
| 86334 |
|
187 |
171 |
$32.86 |
| 83615 |
|
862 |
747 |
$27.66 |
| 74019 |
|
17 |
16 |
$26.91 |
| 87088 |
|
46 |
44 |
$23.09 |
| 99188 |
|
328 |
321 |
$20.00 |
| 82746 |
|
1,448 |
1,386 |
$18.95 |
| 86317 |
|
14 |
12 |
$16.89 |
| 84155 |
|
285 |
270 |
$16.10 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
412 |
380 |
$11.88 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
149 |
141 |
$10.32 |
| 87340 |
|
481 |
467 |
$9.83 |
| 82248 |
|
750 |
621 |
$6.79 |
| C1769 |
Guide wire |
1,433 |
1,270 |
$0.00 |
| A9270 |
Non-covered item or service |
108 |
103 |
$0.00 |
| 36430 |
|
124 |
97 |
$0.00 |
| 82330 |
|
1,128 |
973 |
$0.00 |
| 86160 |
|
14 |
14 |
$0.00 |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
544 |
508 |
$0.00 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
327 |
147 |
$0.00 |
| A9579 |
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml |
247 |
240 |
$0.00 |
| 86225 |
|
12 |
12 |
$0.00 |
| 64494 |
|
108 |
106 |
$0.00 |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
12 |
12 |
$0.00 |
| J2371 |
Injection, phenylephrine hydrochloride, 20 micrograms |
303 |
282 |
$0.00 |
| 88341 |
|
26 |
24 |
$0.00 |
| J3360 |
Injection, diazepam, up to 5 mg |
70 |
63 |
$0.00 |
| 76982 |
|
112 |
106 |
$0.00 |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
198 |
141 |
$0.00 |
| 83883 |
|
39 |
39 |
$0.00 |
| 83521 |
|
150 |
139 |
$0.00 |
| J1630 |
Injection, haloperidol, up to 5 mg |
60 |
52 |
$0.00 |
| 99153 |
Mod sedat endo service >5yrs |
28 |
24 |
$0.00 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
76 |
69 |
$0.00 |
| J1010 |
Injection, methylprednisolone acetate, 1 mg |
15 |
14 |
$0.00 |
| 87536 |
|
51 |
50 |
$0.00 |
| 82378 |
|
30 |
26 |
$0.00 |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
45 |
44 |
$0.00 |
| J8540 |
Dexamethasone, oral, 0.25 mg |
46 |
39 |
$0.00 |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
12 |
12 |
$0.00 |
| 96368 |
|
18 |
14 |
$0.00 |
| 64484 |
|
14 |
13 |
$0.00 |
| J7611 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, concentrated form, 1 mg |
28 |
27 |
$0.00 |
| 96411 |
|
19 |
13 |
$0.00 |
| 94762 |
|
22 |
14 |
$0.00 |
| C9399 |
Unclassified drugs or biologicals |
13 |
12 |
$0.00 |
| 86376 |
|
12 |
12 |
$0.00 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
15 |
14 |
$0.00 |
| C1892 |
Introducer/sheath, guiding, intracardiac electrophysiological, fixed-curve, peel-away |
13 |
13 |
$0.00 |
| 94660 |
|
70 |
12 |
$0.00 |
| 84165 |
|
297 |
282 |
$0.00 |
| 85045 |
|
326 |
296 |
$0.00 |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
748 |
667 |
$0.00 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
12 |
12 |
$0.00 |
| 94729 |
|
546 |
523 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
16 |
12 |
$0.00 |
| 76937 |
|
44 |
40 |
$0.00 |
| 96417 |
|
202 |
106 |
$0.00 |
| J7510 |
Prednisolone oral, per 5 mg |
55 |
51 |
$0.00 |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
818 |
743 |
$0.00 |
| A9505 |
Thallium tl-201 thallous chloride, diagnostic, per millicurie |
151 |
136 |
$0.00 |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
12 |
12 |
$0.00 |
| 86923 |
|
143 |
84 |
$0.00 |
| 83516 |
|
14 |
13 |
$0.00 |
| A9576 |
Injection, gadoteridol, (prohance multipack), per ml |
364 |
350 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
109 |
104 |
$0.00 |
| 82009 |
|
82 |
71 |
$0.00 |
| J1171 |
Injection, hydromorphone, 0.1 mg |
117 |
98 |
$0.00 |
| 87075 |
|
106 |
102 |
$0.00 |
| 12011 |
|
16 |
16 |
$0.00 |
| 86431 |
|
457 |
449 |
$0.00 |
| 62323 |
|
28 |
26 |
$0.00 |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
29 |
25 |
$0.00 |
| Q5106 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units |
32 |
14 |
$0.00 |
| 83020 |
|
26 |
26 |
$0.00 |
| 51701 |
|
58 |
56 |
$0.00 |
| J0897 |
Injection, denosumab, 1 mg |
17 |
14 |
$0.00 |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
41 |
26 |
$0.00 |
| 86200 |
|
12 |
12 |
$0.00 |
| J1953 |
Injection, levetiracetam, 10 mg |
18 |
13 |
$0.00 |
| 86480 |
|
12 |
12 |
$0.00 |
| 80164 |
|
16 |
15 |
$0.00 |